Completed NA INTERVENTIONAL 2-arm NCT00602927

Effects of Varenicline on Brain Activity During Nicotine Abstinence

Neural Substrates of Varenicline's (Chantix®) Efficacy for Smoking Cessation

Sponsor: National Cancer Institute (NCI)

Updated 5 times since 2017 Last updated: May 6, 2011 Started: Nov 30, 2007 Primary completion: Aug 31, 2008 Completion: Aug 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00602927, this NA trial focuses on Nicotine Dependence and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 5 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Pfizer
University of Pennsylvania

Data source: University of Pennsylvania

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Philadelphia, United States